SINOPHARM (01099) has announced the interim financial results for its medical device subsidiary for the six-month period ending June 30, 2026.
The unit recorded operating revenue of RMB 36.492 billion, reflecting a modest year-on-year increase of 0.36%. Operating profit reached RMB 599 million, down 12.34% compared to the same period last year. Comprehensive income attributable to the parent company's shareholders totaled RMB 287 million, a decrease of 2.56% from the prior year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.